Filing Flows › Comparisons › ZNTL vs VRDN
Zentalis Pharmaceuticals vs Viridian Therapeutics: ZNTL and VRDN compared
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $25.8M for Viridian Therapeutics (Q3 2026). Zentalis Pharmaceuticals is more profitable, with an operating margin of -185.6% against -401.8%.
Where the money goes: ZNTL and VRDN
Zentalis Pharmaceuticals (ZNTL) · Q4 2024
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
Viridian Therapeutics (VRDN) · Q3 2026
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
| Zentalis Pharmaceuticals (ZNTL) | Viridian Therapeutics (VRDN) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q3 2026 |
| Revenue | $26.9M | $25.8M |
| Revenue growth, Y/Y | — | -64% |
| Operating margin | -185.6% | -401.8% |
| Net earnings | −$47.5M | −$101M |
| Net margin | -176.7% | -393.0% |
| Operating cash flow | −$39.7M | −$92.8M |
Where the revenue comes from
Viridian Therapeutics
- Product revenue, net: $24.7M (96%)
- Collaboration revenue: $956K (4%)
- License revenue: $125K (0%)
Questions
Which is bigger, Zentalis Pharmaceuticals or Viridian Therapeutics?
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $25.8M for Viridian Therapeutics (Q3 2026).
Is Zentalis Pharmaceuticals or Viridian Therapeutics growing faster?
Zentalis Pharmaceuticals is more profitable, with an operating margin of -185.6% against -401.8%.
More: Zentalis Pharmaceuticals earnings · how Zentalis Pharmaceuticals makes money · Viridian Therapeutics earnings · how Viridian Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 26, 2025; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.